Blood Cancer's Genetic Warning Signs Appear Years Early
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Wellcome Sanger Institute researchers published a Cancer Discovery study showing chronic blood cancers called myeloproliferative neoplasms (MPNs) carry detectable genetic warning signs years before patients develop serious symptoms, based on tracking 30 patients for up to 25 years through more than 450 whole-genome-sequenced samples.
- Patients with stable disease showed genetically "steady" blood cell populations with few new mutations, while those whose conditions progressed to leukemia or myelofibrosis developed additional DNA changes over time — suggesting progression is biologically "encoded" years before clinical deterioration.
- Roughly 10% of MPN patients lack the common JAK2, CALR, or MPL driver mutations, and the study found their blood cell changes resembled normal aging rather than cancer — supporting new British Society for Haematology guidelines that reclassify some as having thrombocytosis rather than blood cancer.
- About 40,000 people in the UK live with MPNs and roughly 4,000 new cases are diagnosed each year; the findings were also presented at the American Association for Cancer Research (AACR) Conference in San Diego.
- Dr. Jyoti Nangalia (senior author) and Dr. Daniel Leongamornlert (first author) led the study, with clinical follow-up at Cambridge University Hospitals NHS Foundation Trust and part-funding from Cancer Research UK.
Why it matters: The study suggests regular genomic monitoring could let clinicians flag high-risk MPN patients years before deterioration, opening a window for earlier intervention. It also questions whether the ~10% of patients without the three common driver mutations — some currently receiving chemotherapy — truly have cancer at all, potentially sparing them unnecessary treatment.
